Testing is performed by Blueprint Genetics. The Comprehensive Hereditary Cancer Panel includes next-gen sequencing of coding regions, exon-intron boundaries, and certain non-coding variants in 146 genes. Deletion/duplication analysis is performed to detect copy number variants (CNVs) ≥1 exon in size. This panel is designed to detect heritable germline mutations and should not be used for the detection of somatic mutations in tumor tissue. Full test details are available here.
Note: Patient signature on the Blueprint Genetics Informed Consent Form is required. Testing will be put on hold until a signed form is received.
This panel provides broad coverage of genes associated with germline susceptibility to cancer. Testing is appropriate for individuals with strong personal and/or family history of cancers.
Peripheral blood: 5 mL in EDTA tube.
Use cold pack for transport. Make sure cold pack is not in direct contact with specimen.